Champions Oncology (STU:2I3) LT-Debt-to-Total-Asset : 0.16 (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Champions Oncology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Champions Oncology's long-term debt to total assests ratio for the quarter that ended in Jan. 2025 was 0.16.

Champions Oncology's long-term debt to total assets ratio declined from Jan. 2024 (0.24) to Jan. 2025 (0.16). It may suggest that Champions Oncology is progressively becoming less dependent on debt to grow their business.

Champions Oncology LT-Debt-to-Total-Asset Historical Data

The historical data trend for Champions Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology LT-Debt-to-Total-Asset Chart

Champions Oncology Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.32

0.24

0.22

0.23

Champions Oncology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.24	0.23	0.23	0.21	0.16

Champions Oncology LT-Debt-to-Total-Asset Calculation

Champions Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2024 is calculated as

LT Debt to Total Assets (A: Apr. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2024 )	/	Total Assets (A: Apr. 2024 )
	=	5.679	/	24.355
	=	0.23

Champions Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2025 is calculated as

LT Debt to Total Assets (Q: Jan. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2025 )	/	Total Assets (Q: Jan. 2025 )
	=	4.833	/	29.586
	=	0.16

Champions Oncology (STU:2I3) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Champions Oncology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Champions Oncology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (STU:2I3) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CSBR:USA 2I3:Germany

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Champions Oncology Headlines

No Headlines